NF Trinity Capital Hong Kong Ltd bought a new position in shares of Unity Biotechnology Inc (NASDAQ:UBX) during the 2nd quarter, Holdings Channel reports. The firm bought 608,060 shares of the company’s stock, valued at approximately $9,157,000. Unity Biotechnology makes up about 1.3% of NF Trinity Capital Hong Kong Ltd’s investment portfolio, making the stock its 17th largest position.

A number of other hedge funds have also made changes to their positions in the stock. Baillie Gifford & Co. purchased a new stake in Unity Biotechnology during the 2nd quarter valued at about $57,274,000. Dean Capital Investments Management LLC purchased a new stake in Unity Biotechnology during the 2nd quarter valued at about $543,000. Gilder Gagnon Howe & Co. LLC purchased a new stake in Unity Biotechnology during the 2nd quarter valued at about $301,000. Finally, Bank of New York Mellon Corp purchased a new stake in Unity Biotechnology during the 2nd quarter valued at about $168,000. Hedge funds and other institutional investors own 9.15% of the company’s stock.

Several analysts have weighed in on UBX shares. Goldman Sachs Group started coverage on Unity Biotechnology in a research note on Tuesday, May 29th. They set a “neutral” rating and a $17.00 price target on the stock. Morgan Stanley started coverage on Unity Biotechnology in a research note on Tuesday, May 29th. They set an “overweight” rating and a $25.00 price target on the stock. Finally, Citigroup started coverage on Unity Biotechnology in a research note on Tuesday, May 29th. They set a “buy” rating and a $32.00 price target on the stock.

Shares of UBX opened at $15.75 on Monday. Unity Biotechnology Inc has a 52 week low of $12.75 and a 52 week high of $20.48.

Unity Biotechnology (NASDAQ:UBX) last issued its earnings results on Thursday, June 7th. The company reported ($4.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($4.36). equities research analysts predict that Unity Biotechnology Inc will post -1.22 EPS for the current year.

Unity Biotechnology Profile

Unity Biotechnology, Inc, a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases.

Featured Article: Trading Strategy Methods and Types

Want to see what other hedge funds are holding UBX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Unity Biotechnology Inc (NASDAQ:UBX).

Institutional Ownership by Quarter for Unity Biotechnology (NASDAQ:UBX)

Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.